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Background: Multiple sclerosis (MS) is a chronic inflammatory disorder of the central nervous system (CNS). It
involves damage to the myelin sheath surrounding axons and to the axons themselves. MS most often presents
with a series of relapses and remissions but then evolves over a variable period of time into a slowly progressive
form of neurological dysfunction termed secondary progressive MS (SPMS). The reasons for this change in clinical
presentation are unclear. The absence of a diagnostic marker means that there is a lag time of several years before
the diagnosis of SPMS can be established. At the same time, understanding the mechanisms that underlie SPMS is
critical to the development of rational therapies for this untreatable stage of the disease.
Results: Using high performance liquid chromatography-coupled mass spectrometry (HPLC); we have established a
highly specific and sensitive selected reaction monitoring (SRM) assay. Our multiplexed SRM assay has facilitated the
simultaneous detection of surrogate peptides originating from 26 proteins present in cerebrospinal fluid (CSF).
Protein levels in CSF were generally ~200-fold lower than that in human sera. A limit of detection (LOD) was
determined to be as low as one femtomol. We processed and analysed CSF samples from a total of 22 patients
with SPMS, 7 patients with SPMS treated with lamotrigine, 12 patients with non-inflammatory neurological
disorders (NIND) and 10 healthy controls (HC) for the levels of these 26 selected potential protein biomarkers. Our
SRM data found one protein showing significant difference between SPMS and HC, three proteins differing
between SPMS and NIND, two proteins between NIND and HC, and 11 protein biomarkers showing significant
difference between a lamotrigine-treated and untreated SPMS group. Principal component analysis (PCA) revealed
that these 26 proteins were correlated, and could be represented by four principal components. Overall, we
established an efficient platform to develop and verify protein biomarkers in CSF, which can be easily adapted to
other proteins of interest related to neurodegenerative diseases.
Conclusions: A highly specific and sensitive multiplex SRM-MS assay was established for development and
verification of CSF protein biomarkers in SPMS. Five proteins were found to be expressed significantly differently
between the three cohorts, SPMS, NIND and HC and 11 proteins associated with lamotrigine treatment, which we
expect will further our current understanding of SPMS disease pathology and/or therapeutic intervention.* Correspondence: rcotter@jhmi.edu
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Multiple sclerosis (MS) is an inflammatory demyelinating
disease of the CNS. During MS, myelin sheaths sur-
rounding axons and the axons themselves are damaged
as a result of chronic inflammation. Such inflammatory
damage creates characteristic focal plaques in the white
matter of the brain and spinal cord [1,2]. Patients with
MS initially present with a host of non-specific neuro-
logical symptoms and there is a high degree of variability
in the early symptoms that patients experience. For
almost all patients, however, early MS associated symp-
toms will occur as a series of relapses and remissions
whereby a patient will remain almost entirely asymptom-
atic for an extended period of time between temporary
symptom “relapses.” Over a variable period of time, MS
will typically evolve from relapsing-remitting multiple
sclerosis (RRMS) into a slowly progressive form of neuro-
logical dysfunction termed secondary progressive multiple
sclerosis (SPMS) [3].
For a complex disease like MS, there is a good reason
to believe that a change in the protein expression profile
occurs long before clinical symptoms are established.
Therefore, protein biomarkers differentially expressed in
MS patients as compared to healthy individuals or
patients suffering from other neurological disorders have
great clinical potential - not only as early diagnostics,
but as potential prognostic markers to be used for moni-
toring disease course and evaluating treatment efficacy
[4-6]. Identification of such markers would also further
our current understanding of MS disease pathology, pin-
pointing novel protein targets or signalling pathways for
therapeutic intervention.
Mass spectrometry-based proteomic technologies have
become preferred laboratory strategies for the discovery
of diagnostic, prognostic, and therapeutic biomarkers
[7,8]. Since the early 1990s, a large number of potential
protein biomarkers have been discovered every year in
labs across the country - in both the academic and the
industry sectors. However, only a handful of these identi-
fied targets are selected for further clinical investigation,
fewer still have been formally validated, and of the thou-
sands of markers that were identified between 2000 and
2005, only five new protein markers were approved by
the US Food and Drug Administration (FDA) for meas-
urement in sera or plasma in that time span [9]. Indeed,
since 1998, the introduction of new protein biomarkers
approved by the US FDA has fallen to an average of one
per year; and this trend continues to be true today des-
pite intensified interest and investment from both aca-
demia and industry. While to some extent, these types
of statistics reflect the inherent time-line needed to con-
duct discovery-based research, it has long been sug-
gested that development of faster and more efficient
biomarker verification strategies could greatly reduce thetime and cost of biomarker-based diagnostic develop-
ment and that the greatest bottleneck to the current bio-
marker pipeline occurs at the verification/validation
stage [10], that is the stage at which purported biomar-
kers, obtained through any number of discovery strat-
egies, are tested quantitatively on samples derived from a
statistically significant number of subjects and controls.
There have been two commonly adopted strategies for
obtaining these kinds of quantitative assays for protein
biomarkers: the enzyme-linked immunosorbent assay
(ELISA) utilizing antibodies to the proteins and mass
spectrometry-based methods that target the predictable
fragmentation of surrogate peptides. Immunoassays
enjoy high specificity and high throughput; however,
they depend critically on the availability of highly spe-
cific antibodies, the development of which is usually
long and costly. In addition, there are technical limita-
tions for multiplexing of immunoassays. In contrast,
quantitative approaches using selected reaction monitor-
ing (SRM) mass spectrometry, have recently drawn in-
tense interest to protein biomarker verification/
validation for advantages of enhanced sensitivity and
specificity, ease of high throughput, and relatively low
cost [8,9,11-15]. Using a tandem mass spectrometer in
which the mass analysers act as two mass filters, one for
the peptide molecular ion mass and the other for a
known sequence fragment, SRM-MS provides a selectiv-
ity and specificity that in many cases enables one to sim-
plify sample preparation by avoiding the initial
immunoprecipitation or fractionation common in many
other mass spectrometry-based strategies.
CSF has been a valuable diagnostic resource for neuro-
degenerative diseases because its composition directly
reflects the metabolic process of the brain. Five proteins
including interleukin (IL)-17 have been recently identi-
fied by Trojanowaski and colleagues as CSF biomarkers
capable of differentiating between two forms of fronto-
temporal lobar degeneration [16]. Similarly, amyloid beta
(1–42), total tau and phosphorylated tau have been
established as biomarkers for diagnosis of Alzheimer’s
Disease (AD). Mattsson and colleagues found that com-
bining biomarkers into a panel leads to a better predict-
ive value than using individual biomarker for the
diagnosis of AD [17]. Interestingly, while the three AD
biomarkers identified by Mattsson, et al. [17] had diag-
nostic value when patient CSF was interrogated, the pro-
teins were either not detected in the peripheral blood or
their measured concentration in plasma did not provide
useful information for diagnosis. Given the results from
the Mattsson study and how varied MS clinical presenta-
tion and disease progression can be across patients, it is
highly unlikely that a single protein biomarker will be
sufficient for a conclusive diagnosis of SPMS. It is
equally unlikely that a single protein would define the
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biomarker dependent diagnosis will require a panel of
disease indicators whereby different indicators will have
greater or lesser diagnostic utility depending upon indi-
vidual patients or stages of disease evolution. As such,
our overall objective is to find a panel of CSF protein
biomarkers that show differential expression profiles
amongst SPMS patients, patients suffering from non-
inflammatory neurological disorders, and disease-free
controls. For the studies presented here, we also
included subjects from the placebo-controlled clinical
trial for lamotrigine as a putative neuroprotective ther-
apy in secondary progressive MS from the UK. Though
this clinical trial did not demonstrate a significant differ-
ence in clinical outcomes between patients taking lamo-
trigine (treated) and the placebo group (untreated) [18],
we believed it was still beneficial to investigate the ex-
pression profiles of CSF protein biomarkers in subjects
of this study to determine if the lamotrigine treatment
has any observable effect at protein level. Based upon
previous discovery results and an up-to-date literature
survey [4,19-21], we selected a total of 26 proteins as po-
tential CSF protein biomarkers for SPMS and developed
a mass spectrometric assay for relative quantitation.Results
CSF samples were obtained from patient cohorts con-
sisting of 12 SPMS subjects from the National Institute
of Neurological Disorders and Stroke (NINDS) at NIH,
10 SPMS subjects from the placebo group involved in
clinical trial of lamotrigine, 12 non-inflammatory neuro-
logical disorder (NIND) controls from NINDS/NIH and
10 healthy controls from the University of Hawaii (see
Table 1). Two biological replicates and three technical
replicates were analyzed by SRM mass spectrometry for
26 biomarkers. The protein biomarkers and the peptide
sequences monitored, the specific fragmentation transi-
tions, the optimized collision energy (CE) and the start/
stop times in a scheduled SRM experiment are listed in
Additional file 1: Table S1. Intact horse apomyoglobin
was used as an internal standard for quantitation.Table 1 Age, gender and diagnosis group for the 51
subjects
Group Gender Age (years)
# Female # Male Mean Range
HC 2 8 45.4 27-52
NIND 11 1 45.5 29-59
SPMS(1) 13 9 53.8 33-69
SPMS (treated) (2) 5 2 53.9 44-60
(1)includes 12 NINDS and 10 lamotrigine placebo subjects.
(2)treated with lamotrigine.Limit of detection, retention time and peak area
reproducibility
The first experiments determined the limit of detection
and measurement reproducibility using horse apomyoglo-
bin as internal standard. After optimization of the sample
preparation, injection volume, flow rate andchromatogra-
phy, the final method used 5-fold concentrated CSF, 1μL
partial loop injection, 20 μL/min flow rate, a total of 32
min gradient run with a four minutes scheduling window.
Intact horse apomyoglobin was serially diluted and added
to CSF to obtain the standard curve shown in Figure 1.
From this, the LOD was determined as one fmol/μL. These
measurements monitored the peptide HGTVVLTALG-
GILK MH2
+2 ion transitions to the y8, y9 and y10 fragment
ions at a retention time of 33 min as shown in Figure 2.
Retention time reproducibility (Figure 3a) and peak area
reproducibility (Figure 3b) for all surrogate peptides were
obtained for their three technical replicates.Differential expression profile of selected protein
biomarkers in SPMS, NIND and healthy controls
The peak area results for all 26 surrogate peptides, aver-
aged for both biological and technical replicates for all
patient and control samples are shown in the Additional
file 2: Table S2 along with their standard deviations. Ana-
lysis of variance (ANOVA) indicated that five protein
biomarkers: amyloid beta A4 protein (A4), alipoprotein E
(APOE), kallikrein 6 (KLK6), putative myosin-XVB
(MY15B) and pigment epithelium-derived factor (PEDF)
were associated with diagnosis (Table 2). Post-hoc mul-
tiple comparisons showed that the expression of bio-
marker MY15B was significantly lower in SPMS than
HC. The expression of three biomarkers, A4, APOE and
KLL6, were significantly lower in SPMS than NIND
group. The expression of biomarker MY15B and PEDF
were significantly lower and higher in NIND than HC,
respectively.Figure 1 Standard curve for digested horse apomyoglobin in
CSF: x-axis is the concentration of horse apomyoglobin; y-axis is
the peak area under the curve detected by LC-MS/MS; insert is
the calibration equation with R2 as the correlation coefficient.
Figure 2 Representative selected reaction monitoring (SRM) spectrum for the peptide HGTVVLTALGGILK from horse apomyoglobin.
Precursor: 689.9245++, Product Ions: [y10] - 984.6452+, [y9] - 885.5768+ and [y8] - 772.4927+. Each color-coded trace represents one transition.
x-axis is time; y-axis is ion intensity.
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biomarkers in lamotrigine trial
Lamotrigine treatment effect in expression was assessed
by comparing treated (7 SPMS patients) with untreated
(22 SPMS patients) group (Table 3). Eleven proteins
were found to have a significant difference in expression
between the treated and untreated SPMS group, and all
11 proteins in the treated group had lower expression
compared to untreated group, indicating lamotrigine
therapy had the effect of decreasing expression of these
proteins.
Principal component analysis
Based on the eigenvalue greater than one rule, four prin-
cipal components accounted for 85.9% of total variance
were extracted (RPC1, the first rotated principle compo-
nent, accounted for 45.9%, RPC2 for 18.6%, RPC3 for
13.7%, and RPC4 for 7.7%), thus, the information in the
26 biomarker variables could be represented by only
four components and the four components were used to
assess the difference among the three diagnostic categor-
ies. According to the component loadings (the correl-
ation coefficients between a component and a protein),
most of proteins were highly correlated to only one
component. Therefore, the 26 proteins could be clus-
tered into four groups as shown in Table 4. By ANOVA,
significant difference between SPMS and NIND was
observed in RPC2 and that between SPMS and HC in
RPC4 (Table 2). The five biomarkers with significant ef-
fect of diagnosis in Table 2 were highly correlated with
either RPC2 or RPC4.Discussion
By taking the advantage of high specificity and sensitivity,
we have developed a multiplex SRM assay for detecting
even low abundant proteins in CSF with relatively simple
sample preparation. The platform we have developed here
can be easily adapted to other protein biomarker studies.
The sensitivity and throughput might be further enhanced
using newly developed technologies, such as the dual stage
electrodynamic ion funnel interface described by Hossain
et al. [22]. Although our assay successfully quantified both
high abundant and low abundant proteins in CSF, several
proteins which have been previously reported present in
CSF were not detected during our initial method develop-
ment using pooled CSF, such as nidogen-2 (NID2) and ni-
tric oxide synthase (NOS2). Low abundance might be one
of the contributing factors, though the intrinsic biological
properties of the pooled CSF and the instability of pep-
tides/proteins are also possible. Improvements in sample
preparation and optimization of instrument parameters
could increase the appearance of low abundant proteins in
future studies.
The human proteome is more complex, compared to
the genome, considering that each protein can be
present in different isoforms even at the same time.
However, mass spectrometry-based targeted proteomics
has the advantage of specifically quantifying individual
protein isoform, which could potentially help us better
understand the pathogenesis underlying various diseases.
Although we did not include such studies here, the in-
trinsic specificity of SRM provides the merit to do so if
necessary in the future.
Table 2 Protein biomarkers and selected principal components with significant difference between three groups
(p<0.01)
A4 APOE KLK6 MY15B PEDF RPC2 RPC4
SPMS vs. HC Ratio(1) 0.88 1.15 1.04 0.33 1.26
p(2) 0.7811 0.9358 0.9909 <0.0001 0.2423 0.9742 <0.0001
SPMS vs. NIND Ratio(1) 0.55 0.58 0.62 0.74 0.81
p(2) 0.0084 0.008 0.004 0.0502 0.1288 0.0093 0.1117
NIND vs. HC Ratio 1.61 1.97 1.67 0.44 1.55
p(2) 0.1178 0.0136 0.0131 0.0004 0.0087 0.0529 0.0424
F-test (df=2) p(3) 0.0078 0.0032 0.0019 <0.0001 0.0083 0.007 <0.0001
(1)ratios of two group medians.
(2)p-value of pairwise comparison adjusted with Scheffe’s method.
(3)p-value of global F-test for main effect of diagnosis (10 HC, 12 NIND and 22SPMS).
Figure 3 LC-MS/MS method reproducibility. (a) Retention time reproducibility. Each surrogate peptide is represented on the x-axis by one
letter abbreviations of its first three amino acid residues. The three transitions for each peptide are represented in different colors. y-axis is
retention time. Data shown are an average of a triplicate. (b) Peak area reproducibility. x-axis is peptide; y-axis is peak area in log scale.
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Table 3 Protein biomarkers with significant difference














(1) p-value of ANOVA (7 treated vs. 22 untreated SPMS subjects).
(2) The ratios of untreated to treated group median.
Table 4 Protein biomarker variable loadings on the four
rotated principal components
Protein RPC1 RPC2 RPC3 RPC4
1433F 0.938 0.123 0.233 0.096
NFL 0.889 0.215 0.300 0.136
A2MG 0.765 0.502 -0.167 0.114
1433B 0.742 0.349 0.088 -0.031
RTN4 0.560 -0.366 0.212 0.443
CNTN1 -0.591 -0.532 0.513 -0.103
AMD -0.804 0.043 0.213 0.196
1433G -0.808 0.106 -0.335 0.107
CAD13 -0.819 -0.246 -0.318 -0.210
AACT -0.880 -0.177 -0.107 -0.114
NRCAM -0.885 -0.239 -0.303 -0.028
KLK6 0.184 0.941 0.081 -0.020
VGF -0.134 0.935 -0.008 -0.006
MOG 0.334 0.878 0.176 -0.017
PEDF 0.329 0.780 0.307 0.087
A4 0.099 0.740 0.341 -0.187
APOE 0.655 0.690 -0.121 -0.065
SODC 0.227 0.663 -0.606 0.249
OSTP -0.027 -0.037 0.925 0.081
SAMP 0.421 0.287 0.791 0.257
TAU 0.487 0.243 0.770 0.246
NFH 0.552 0.110 0.764 0.222
NFM 0.369 0.348 0.701 0.185
KLKB1 -0.010 0.117 0.448 0.864
AGRIN 0.023 0.112 0.450 0.862
MY15B -0.046 0.298 0.290 -0.652
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eases, there were some concerns in the process of search-
ing for protein biomarkers in CSF, such as low protein
abundance, difficulties in collecting samples, spontaneous
variation through the day, etc. It is essential that CSF col-
lections follow standard operating procedures, including
but not limited to the following: all lumbar punctures
were carried out at approximately the same time of day,
and sample processing (e.g. time to centrifugation, centri-
fugation speed and time) and storage was handled in a
standard way. Our study was carried out among a limited
number of patients since the purpose of our study was to
validate the feasibility of using SRM for protein biomarker
verification. In the future, validation studies on large
cohorts of samples originating from healthy controls,
relapse-remitting MS (RRMS), SPMS, primary-progressive
MS (PPMS), NIND and other inflammatory neurological
disease (OIND) controls will determine clinical value of
this pilot combinatorial biomarker.Conclusions
Using SRM to target a specific set of surrogate bio-
marker peptides, we established a highly sensitive and
specific multiplex assay to simultaneously detect twenty-
eight potential protein biomarkers which might be
involved in the pathology of SPMS. We quantified the
relative levels of each targeted protein using an internal
standard horse apomyoglobin and compared their ex-
pression profiles among three different cohorts: SPMS,
NINDS and healthy controls. ANOVA indicated one
protein biomarker- showing significantly different ex-
pression between SPMS and HC, and three protein bio-
markers showing significantly different expression
between SPMS and NIND. It is highly possible that these
four proteins play a role in the pathophysiology of SPMS
and could potentially benefit the diagnosis, prognosis
and/or the development of newer generation treatments.
In addition, two proteins were expressed differently be-
tween NIND and healthy controls, which could poten-
tially benefit NIND studies. In the lamotrigine trial,
although the trial itself came negative with respect to
the efficacy of the drug therapy, our analysis suggested
that eleven proteins in the treated group had signifi-
cantly lower expression compared to the untreated
group. Since lamotrigine therapy had an effect of de-
creasing expression for these proteins, it is plausible that
these proteins are correlated with other proteins. In fact,
our principal component analysis (PCA) revealed that
these 26 proteins were correlated, and could be repre-
sented by four principal components.Overall, we have
established a straightforward mass spectrometry-based
platform for CSF protein biomarker development and
verification. This platform can be easily adapted to study
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interest to neurodegenerative diseases.
Methods
Subjects and clinical samples
CSF samples involved in our study included a coded cohort
of 12 untreated SPMS patients and untreated 12 non-
inflammatory neurological disorders (NIND) controls from
the Neuroimmunology Branch of the National Institutes of
Neurological Disorders and Stroke (NIB/NINDS/NIH) col-
lected under natural history protocol 09-N-0032, healthy
controls from University of Hawaii, and SPMS patients
from a UK double blinded lamotrigine trial (active arm and
placebo). All patients signed informed consent and all
research procedures were approved by the institutional
review boards (IRB) of afore-mentioned institutions.
Cerebrospinal fluid sample preparation
NIB samples were transported to the laboratory on ice
and spun (3000 g x 10 min) within 30 min of collection.
Cell-free supernatants were sequentially coded and im-
mediately cryopreserved at −80°C in 500 μl aliquots.
Prior to all sample preparation, we prepared a stock of
1pmol/μL of horse apomyoglobin in deionized water to
be used as an internal standard spiked into all CSF sam-
ples. Prior to tryptic digestion of the CSF samples used
both in method development and then in our cohort
screening experiments, 100 μL of 0.1% Rapigest (Waters,
Milford, MA) resuspended in 100 mM ammonium bi-
carbonate, 2 μL 500 mM dithiothreitol (DTT), and 10
μL of the 1pmol/μL stock of the internal standard, horse
apomyoglobin, were added to each individual 100 μL
CSF aliquot. To reduce protein disulfide bonding, each
sample aliquot was heated at 60°C for 30 min. After
allowing each sample cool down to room temperature,
10 μL of 200 mM iodoacetamide (IA) was added. Each
vial was placed in the dark for 30 min to allow for alkyl-
ation of all free protein cysteine residues. 5 μL of trypsin
(0.2 μg/μL in 1 mM HCl) was then added to each sam-
ple following the DTT reduction and IA alkylation steps.
The sample mixtures were incubated at 37°C for 18 h to
allow for complete enzymatic digestion of the CSF and
the protein standard horse apomyoglobin. Following
trypsinization, 2 μL of trifluoroacetic acid was added to
the digestion mixture to quench the reaction. The sam-
ples were then incubated at 37°C for an additional 45
min. Following this second incubation step, samples
were speed-vacuumed to dryness, reconstituted in 0.1%
formic acid in deionized water, and desalted using
Waters Oasis HLB solid phase extraction cartridges
(Waters, Milford, MA) according to the manufacturer’s
protocol with a vacuum manifold. To prepare for LC-
MS analysis, the eluents from the solid phase extraction
were speed-vacuumed to dryness and reconstituted with20 μL 0.1% formic acid in water. Pooled CSF samples
obtained from patients without identified medical
records were used during the initial stages of method
development. All reagents were added to practice CSF in
proportion as described. Diseased CSF and healthy con-
trol CSF samples selected for inclusion for our cohort
screening experiments were obtained from patients with
complete associated medical records. Individual CSF
patient samples used during cohort screening were
blinded prior to any sample processing. Additionally,
sample aliquots were prepared in parallel and as dupli-
cates to minimize experimental error during sample
preparation. All reagents were purchased from Sigma if
not mentioned specifically.
HPLC separations
Prior to our selected reaction monitoring assay develop-
ment efforts, the RP-HPLC gradient profile used for sep-
aration of digested CSF samples was first optimized. An
Agilent ZORBAX SB-C18 column (150 X 0.5 mm, 5 μm)
(Agilent Technologies Inc., Santa Clara, CA, USA) was
attached to a Waters Nano-Acquity ultra-high pressure
HPLC (Waters, Milford, MA, USA) and placed in the
front end of our Thermo Vantage Triple Quadrupole
mass spectrometer (Thermo Fisher Scientific, Waltham,
MA). Total Ion Chromatograms of the various c18 RP-
HPLC separations were acquired in full scan mode acqui-
sition with a scan time of 0.5 s. Ultimately, we selected a
32 min RP-HPLC linear gradient to be used for all subse-
quent CSF sample separation whereby the injected pep-
tides were eluted with the following gradient: the first 2.4
min post-injection were diverted to waste with a 3% B
hold, a linear 3-45% B gradient was performed in the
next 22.6 min, a linear 45-90% B gradient ramp was per-
formed in 1 min followed by a 90-100% B linear ramp in
1 min, 100% B was held for 1 min before a linear gradient
of 100-3% B was performed in 2 min followed finally by a
3% B hold for 2 min. Solvent A consisted of 0.1% formic
acid in water and solvent B consisted of 90% acetonitrile,
10% water and 0.1% formic acid. The flow rate of the
Nano-Acquity HPLC was set at 20 μL/min.
LC-MS/MS method
Intact horse apomyoglobin was chosen as a model pro-
tein to establish the LOD of our multiplex SRM LC-MS/
MS method. Digested horse apomyoglobin was diluted
in serial in digested CSF with concentrations ranging
from 1 fmol/μL to 100 fmol/μL. Using a CSF sample
with 100 fmol/μL of digested horse apomyoglobin, the
following was experimentally determined: the signature
tryptic peptide NDIAAK was selected as the surrogate
peptide for the apomyoglobin protein, the three most
abundant detected transitions of peptide NDIAAK, ions
y3, y4, and y5 were selected for detection in Q3, and of
Jia et al. Clinical Proteomics 2012, 9:9 Page 8 of 9
http://www.clinicalproteomicsjournal.com/content/9/1/9those three, the most abundant, y3, was selected for
generating a standard curve for this peptide. A serial of
apomyoglobin dilutions were then subject to LC-MS/MS
analysis with Q1 mass filter targeting detection of the
parent ion of NDIAAK and Q3 mass filter targeting
detection of the three selected product ions. Ions were
introduced into the mass spectrometer via an H-ESI II
probe outfitted with a 32 gauge needle (Thermo Fisher
Scientific, Waltham, MA, USA). Instrument operating
parameters used during acquisition were as follows: ca-
pillary temperature of 270°C, vaporizing heat was shut
off, sheath gas pressure was set at 10, no auxiliary gas was
used, and the spray voltage was set to 4,000 V. Instrument
settings in Xcaliber were as follows: positive scan mode,
scan widths of 0.004 m/z, scan times of 0.015 s, chrom fil-
ters enabled and set at 50, collision gas set at 1.5mTorr, Q1
peak width (FWHM) of 0.7, Q3 peak width of (FWHM)
0.7, and cycle times of 5 s (Xcaliber v 2.1, Thermo Fisher
Scientific, Waltham, MA, USA). Following data acquisi-
tion, peak areas under the curve were calculated using
an open source proteomic software platform Skyline [23]
(Skyline v. 1.1, MacCoss Lab, Seattle, WA) and a linear
standard curve (y= 5884.7x-9111.7, R2 =0.9998) was gen-
erated using Microsoft Excel (Figure 1).
LC-MS/MS method development and optimization
Using a Waters ultra-high pressure reverse phase high
performance liquid chromatography (Waters nanoAC-
QUITY UPLC, Milford, MA, USA) outfitted with an
Agilent ZORBAX SB-C18 column (150 X 0.5 mm,
5 μm) (Agilent Technologies Inc., Santa Clara, CA,
USA) and coupled to a Thermo Fisher triple quadrupole
mass spectrometer (Thermo TSQ Vantage, Thermo
Fisher Scientific, Waltham, MA, USA), we designed a
multiplexed peptide based selected reaction monitoring
(SRM) assay using the RP-HPLC and mass spectrometric
settings mentioned in the two previous method sections.
Our SRM assay allows for the simultaneous relative
quantification of 26 tryptic peptides originating from
proteins implicated in SPMS pathology. FASTA files for
selected protein biomarkers were downloaded from Uni-
prot (www.uniprot.org) individually and imported into
Skyline. The uniqueness of the selected surrogate pep-
tides was confirmed by running individual BLAST search
from NCBI website (http://blast.ncbi.nlm.nih.gov/Blast.
cgi). Instrumental methods were exported from Skyline
into a Thermo Xcaliber 2.1 “EZ SRM” method template
with the same settings as used during data acquisition
for our LOD determination experiments (Xcaliber v. 2.1,
Thermo Fisher Scientific, Milford, MA, USA). To design
our SRM assay, we adopted an iterative method develop-
ment strategy, eliminating poor performing transitions
from the SRM assay in a targeted method refinement
cycle [23]. Raw data was inspected in the Skylinesoftware platform and the peak areas of each detected
transition were normalized to that of horse apomyoglo-
bin peptide HGTVVLTALGGILK. Starting with an initial
1885 transitions for 403 surrogate peptides, we com-
pleted seven rounds of iterative method refinement to
generate the final SRM assay. The final SRM assay was a
scheduled method consisting of 78 transitions for 26
peptides with a scheduling window of four minutes - no
more than 50 concurrent transitions were detected at
any given time. Reproducibility was confirmed by run-
ning four replicates. Both retention time and peak area
are highly reproducible (Figure 3a and 3b).
Data analysis
Box-Cox transformation was applied to CSF values of
the 26 biomarkers. Age and gender were considered as
covariates, p-value of 0.1 was used for covariate selec-
tion. Analysis of variance (ANOVA) with or without
covariates was performed to assess the differences in the
CFS biomarkers values between three cohorts (22 SPMS,
12 NIND and 10 HC), followed by Scheffe’s pair-wise
comparison of means. ANOVA was also applied to
assess the effect of lamotrigine therapy on the expression
of 26 protein biomarkers by comparing 22 SPMS
patients with 7 lamotrigine treated SPMS patients.
The relationship between the 26 biomarkers was esti-
mated by Pearson correlation coefficients. Since these
biomarkers were found to be closely correlated, principal
component analysis (PCA) with Varimax rotation was
performed to represent the 26 biomarkers as a set of
new orthogonal variables, and subsequently, ANOVA
with or without covariates was applied to the selected
principal components.
A significant level of 0.01 was used in order to adjust
for multiple testing. The statistical analyses were per-
formed using SAS version 9.2.
Additional files
Additional file 1: Table S1. Peptides and transitions used in SRM
Additional file 2: Table S2. Peak areas averaged for both biological and
technical replicates and standard deviations for the 26 surrogate
peptides.
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